Oral insulin program continues to advance with topline efficacy data expected in H2 2022 - Significant value creation opportunities through oral COVID-19 vaccine program and partnerships - Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3, 2021

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. To see a video message from the CEO please click here: https://www.youtube.com/watch?v=vgq1I7ylKsk

Gurugram-based Premas Biotech has signed a licensing deal with Oravax Medical for the development and commercialisation in India, of its virus-like-particle COVID-19 vaccine technology.

Oravax Medical has taken an early step toward the commercialization of its oral COVID-19 vaccine by entering into a deal to ship 10 million doses of the clinical-phase candidate to Southeast Asia.

Premas Biotech has licensing deal for virus-like particle (VLP) injectable vaccine technology for COVID-19, with Oravax for commercialization in India

The Oravax oral vaccine candidate has received clearance from the South African Health Products Regulatory Authority

GURUGRAM, India--(BUSINESS WIRE)--Premas Biotech (https://www.premasbiotech.com/) announced today that its joint venture Oravax will initiate testing of their oral virus-like particle (VLP) vaccine candidate against Omicron variant of SARS-CoV 2 virus through preclinical, in vitro and challenge studies to assess its efficacy for the new mutant strain. Premas Biotech, Oramed Pharmaceuticals, MyMD Pharmaceuticals, and certain other shareholders formed Oravax Medical to bring an oral COVID-19 vaccine to the market. (https://ora-vax.com/)

Recently, Oravax Medical Inc., ("Oravax" has entered into a licensing agreement with Premas Biotech to make available for commercialization of Oravax's virus-like particle (VLP) vaccine technology. Oravax is a joint venture between Oramed Pharmaceuticals Inc., a US-based company (the majority shareholder), and Gurugram, India-based life sciences company, Premas Biotech ("Premas"). While the terms of the license agreement have not been disclosed, Oravax will be entitled to royalties upon commercialization of this vaccine in India.

Gurugram-based Premas Biotech, which developed a virus-like particle (VLP), is looking to find a solution to prevent Covid through an oral vaccine, in partnership and collaboration with an Israeli company, Oramed Pharmaceuticals.

Oramed Pharmaceuticals Inc has joined forces with Biotechnology company Premas Biotech to develop an oral vaccine for COVID-19, according to a Friday press release from Business Wire.

Premas is developing the vaccine while Israeli partner Oramed is working on delivering it in oral form. JV firm applying for phase-1 trials in many countries.

Gurugram-based biotechnology firm Premas Biotech is developing a Covid-19 vaccine candidate in the form of an oral capsule, the firm's managing director Prabuddha Kundu told ThePrint. The company has partnered with the Jerusalem-headquartered Oramed Pharmaceuticals.

A collaboration between Gurugram-based biotechnology firm Premas Biotech and Israel's Oramed Pharmaceuticals has reportedly developed an oral vaccine that can be swallowed like a pill instead of an injection which is the current norm, a report in The Hindu said.

Premas Biotech’s potential COVID-19 vaccine is the first one globally to adopt a triple-antigen approach, which is designed to produce an enhanced immune response.

Premas Biotech announced that its triple-antigen vaccine candidate for COVID-19 has induced neutralising immune response in mice during the four-week test of its SARS-CoV-2 vaccine candidate.

Gurgoan-based biotech Premas Biotech is the latest entrant into the COVID-19 vaccine race. Unlike single-protein vaccines currently under trials across the world, Premas Biotech is developing a multi sub-unit vaccine with three antigens.

The company is in talks with the Indian regulatory authorities concerned to plan and initiate next steps towards conducting human trials, Premas Biotech said in a statement.

Premas Biotech, a developer of novel biotherapeutic and vaccine candidates, has announced the development of an oral Covid-19 vaccine that has shown efficacy after a single dose, in conjunction with Oramed Pharmaceuticals Inc.

Premas Biotech, a developer of novel biotherapeutic and vaccine candidates, announced today the development of an oral COVID-19 vaccine that has shown efficacy after a single dose, in conjunction with Oramed Pharmaceuticals Inc.

Oravax’s COVID-19 vaccine candidate which is a triple antigen virus like particle (VLP) consists three structural proteins of SARS-CoV2, unlike most other vaccines that are based on Spike (S) protein.

Premas Biotech, a Gurugram-based biotechnology firm and Oramed Pharmaceuticals, a Jerusalem headquartered company, have a long standing collaboration on developing new drug delivery techniques.

Premas Biotech, the Gurgaon-based Biotech company which developed the triple antigen virus-like particle (VLP) vaccine candidate for SARS CoV-2 virus, said it had progressed into animal trials.

Israel-based Oramed and India’s Premas Biotech are jointly working on a Covid-19 vaccine that can be taken orally, like a pill.

Gurgaon-based Premas Biotech has successfully completed its vaccine prototype by obtaining transmission electron microscopic (TEM) images of the recombinant virus-like particle (VLP) assembled by using an exclusive D-Crypt™ technology, which employs the highly scalable and cost-effective baker’s yeast as a platform.

Oramed Pharmaceuticals and Prema Biotech have formed Oravax Medical, a joint venture focused on developing oral COVID-19 vaccines.

Amidst the resurgence of COVID-19 that is creating fear among people in the country, here’s good news that an oral vaccine in capsule form has been developed for the deadly virus.

In an emerging wave of new COVID vaccines – known are the ones that require only one shot instead of the two at present; and oral capsules that would obviate jabs – there is another one: nasal spray. Reuters has reported that Israel and New Zealand have given interim approval for the sale of SaNOtize Research and Development’s Nitric Oxide Nasal Spray (NONS).

Gurugram Premas Biotech, a developer of novel biotherapeutic and vaccine candidates, has recently announced the development of an oral COVID-19 vaccine that has shown efficacy after a single dose, in conjunction with Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals of Jerusalem and Premas Biotech of India form new company to develop revolutionary coronavirus inoculation.

Premas Biotech and Oramed announce oral Covid-19 vaccine candidate that produces antibodies after a single dose.

The race to end the global pandemic isn’t over. Innovation continues as a company, Oravax Medical, a new joint venture of the Israeli-American company Oramed and the Indian company Premas Biotech, started testing a pill for an oral COVID-19 vaccine. Dr. Joseph Allen with Premier Health said if approved, it will be a game-changer.

Premas Biotech, a Gurugram-based biotechnology firm and Oramed Pharmaceuticals, a Jerusalem headquartered company, have a long standing collaboration on developing new drug delivery techniques.

Throughout history, breakthroughs in technology have come from companies which are bold, visionary and have the ability to bring about revolutionary thinking. In Episode 8 of #Biotalknology, we feature three such companies, whose founders have demonstrated vision, courage & a laser focus on realising their purpose.

We introduce Dr. Prabudha Kundu, Co-founder and Managing Director of Premas Biotech, at the Global Bio-India 2021. Join him as he shares his knowledge on "various emerging technologies under biotechnology covering areas including Health, Food, Energy and Environment."

Dr. Prabuddha Kundu, Co-founder, and Managing Director of Premas Biotech will speak at a virtual symposium on 29th April 2021, Thursday. Organized by IIT Roorkee, the session will focus on the theme

Join Dr Prabuddha Kundu, Co-Founder and MD at Premas Biotech for a 30 min talk at Indian Biopharma Leaders Conclave 2021; 10.45 am on Thursday, 21st May 2021. Dr. Kundu will be talking about "Developing the world's first triple antigen Virus-Like Particle (VLP) against SARC CoV-2 Virus, and oral delivery."

Dr. Prabuddha Kundu, Co-founder, and Managing Director of Premas Biotech will speak at the upcoming 5th Annual MarketsandMarkets Bioprocessing of Biotherapeutics - UK, EU & APAC - Virtual Conference scheduled to be held on 20th May 2021. Join him as he shares his knowledge on "Developing the world’s first triple antigen Virus-Like Particle (VLP) against SARS CoV-2 virus, and oral delivery."

Dr. Prabuddha Kundu, Co-Founder, and MD of Premas Biotech will speak on June 16th, 2021, at a webinar hosted by Birla Institute of Technology and Science, Pilani. The session will concentrate on "Developing the world's first triple antigen Virus Like Particle (VLP) against SARS CoV-2 virus and oral delivery."

Dr. Prabuddha Kundu, Co-Founder, and MD of Premas Biotech, along with Mr. Nadav Kidron, CEO, Oramed Pharmaceuticals, will present the keynote talk on August 5th, 2021, at Virtual Vaccines Conference 20-21. Join us at 9 am EST / 6 pm IST at the virtual event to hear the keynote on development of the world’s first triple antigen oral SARS Cov-2 vaccine.

Premas is proud to be featured on upcoming Grand Rounds: a Webinar in Biotech and Specialty Pharma hosted by James Molloy, Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals at Alliance Global Partners on Monday, April 26, 2021 at 8:30 PM IST/11 AM EST.

Join us for Dr. Prabuddha Kundu's speaker session at Biosimilar workshop digital edition 2021 on “Advances in Diagnosis, Therapeutic interventions and analytical characterization of SARS-CoV-2 Virus” on 7th Oct, 2021 from 3:55pm-4:40pm.